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Summary.-I.p. administration at several dose levels over periods of up to 12 weeks,
or continuous i.v. infusion of high doses ofmisonidazole (MISO) for 15 h, produced no
significant change in peripheral nerve conduction velocity (NCV) and did not prevent
the normal increase in NCV as the animals matured from 12 to 24 weeks of age.
Peripheral NCV (sural nerve) was reduced in both MISO-treated and control mice
with hind-limb tumour implants, presumably owing to physical pressure due to
tumour growth. In addition, neither the medial nerves nor the tibial nerve in the
normal limbs of the tumour-implanted, drug-treated animals showed any change.
Consequently our earlier and present studies do not confirm the recent reports of
changes in NCV following either acute or chronic MISO administration to mice.
MISONIDAZOLE (Ro-07-0582, MISO) a
drug capable of radiosensitization of
hypoxic tumour cells (Rauth & Kaufman,
1975; Fowler et al., 1976; Denekamp &
Fowler, 1978) when tested in normal
human volunteers did not demonstrate
any serious toxic side effects from single
doses of 1-4 g (Foster et al., 1975), but in
subsequent studies on cancer patients
receiving multiple doses, symptoms of
glove and stocking parasthesia were re-
ported (Dische et al., 1977; Urtasun et al.,
1977). At high drug doses, convulsions
were noted (Saunders et al., 1978). Motor-
nerve conduction velocities (motor NCV)
were found to be normal but occasionally
borderline (Kogelnik et al., 1978). A sural-
nerve biopsy on a single patient appar-
ently demonstrated some degree of distal
axonal degeneration and remyelination
(Urtasun et at., 1978). The most recent
clinical studies suggest that the maximum
tolerated dose before the appearance of
neuropathological symptoms is 12-15
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g/m2 and independent of the dose frac-
tionation when administered over a period
of 3-6 weeks (Wasserman et al., 1979).
In the mouse, Hirst et al. (1978) re-
ported that a single i.p. injection of
MISO significantly decreased the motor
NCV. These findings could not be con-
firmed when the temperature of the nerve
was strictly controlled (Von Burg et al.,
1979). However, we have investigated
the possibility that electrophysiological
changes may occur on extended dose
regimens. The mouse was used in this
study, since the efficacy of MISO as a
radiosensitizer has been extensively in-
vestigated in this model system.
MATERIALS AND METHODS
Source of animals.-Female BALB/cKa
mice (18-20 g) were purchased from Bio-
breeding Laboratories (Ontario, Canada).
The animals were housed in plastic boxes in a
temperature- and humnidity-controlled room
and fed food and water ad libitum. T'heP. J. CONROY ET AL.
number ofanimals used in each experiment is
indicated in the Table or in the text.
Preparation of drug and dosing regimen.
MISO was supplied by the Drug Synthesis
and Chemistry Branch, Division of Cancer
Treatment, National Cancer Institute,
Bethesda, MD. The drug was dissolved in
phosphate-buffered saline (PBS), pH 7 4, and
passed through a 0-22,tm Millipore filter.
Drug solutions were prepared each day.
In the acute experiments, where MISO was
administered i.p., mice received either 0-5
mg/g/day (0 5 ml of a 20mg/ml solution) or
1 mg/g/day (1-0 ml) on alternate days for a
total administered dose of 4 or 5 mg/g (12 or
15 g/m2). Control mice received equivalent
volumes of PBS. All injections were made at
the same time each day (10:00 a.m.). Peri-
pheral NCV and other electrophysiological
determinations were made 24 h after the last
MISO injection, to allow for clearance of the
drug from the serum. For studies involving
administration of MISO by continuous i.v.
infusion, mice were infused with a 30mg/ml
solution in PBS (pH 7 4) at a rate of 04125
ml/h for 15 h. The method used was a modifi-
cation of that described by Paul & Dave
(1975). Control mice received PBS (pH 7-4)
at the same rate ofinfusion (04125 ml/h). The
MISO serum concentration ingroups of4 mice
at 3, 9, and 15 h after the i.v. infusion ofdrug
wasdetermined withaUVspectrophotometric
method previously described (Von Burg et al.,
1979). The mean MISO serum levels at these
times were not significantly different from
each other (P>0 9, 2-tailed Students t test).
The pooled mean MISO serum level was
443+32 ,tg/ml (s.d.). Peripheral NCV meas-
urements were made on animals immediately
after 15 h of continuous i.v. infusion of
MISO or PBS, or 6 h after the completion of
the infusion (21 h). The serum level ofdrug in
the MISO-infused mice at 21 h had declined
to 51 + 10 ,tg/ml (s.d. 4 mice).
For the studies concerned with chronic
exposure of mice to MISO, the drug or an
equivalent volume of PBS (injection volume
0 3 ml) was administered i.p. 5 times weekly
(total weekly dose 1-5 mg/g or 4-5 g/m2) for
up to 12 weeks. Peripheral NCV and other
electrophysiological parameters were meas-
ured 24 h after the last MISO or PBS injection
for each group sampled.
Electrophysiological recording: Isolated pre-
parations.-The method for surgical isolation
ofthe sural and tibial nerves, and the record-
ing techniques, have been reported by Von
Burg et al. (1979). Peripheral NCV and re-
fractory times were measured. The overall
error in any one determination of peripheral
NCV from all sources is estimated to be
10%. Therefore, the method is not appro-
priate for measuring minor changes in NCV
of 20% or less with a high level of confidence
(P<0 05). However, it is useful for estimating
NCV changes equal to or greater than 20%.
The refractory time measurements were
made to an accuracy level of 0-1 msec (100
,usec). No significant difference was found
(P>0 9, Students' t test) in refractory time
between any of the 10 experimental groups
reported in the Table (pooled mean, 0 40+
0 03 msec).
Since nerve tension could affect the length
of nerve under study and hence the calcula-
tion ofthe velocity (stimulus artefact to peak)
a series of isolated sciatic-tibial nerves (12 in
total from 6 mice) was stretched and the
action-potential latency was determined at
length increments of 1, 2, and 3 mm. Initial
length was established as reported by Von
Burg et al. (1979). Additional length was
measured by means of a micrometer scale on
a micromanipulator. Expressed as a per-
centage of the initial control NCV at the
starting length (typically 641 + 1 1 mm) length
increments of 1, 2, or 3 mm increased the
mean NCV by 0 8% (2 determinations),
1.3% (10) and 4.2% (3) respectively, and are
not statistically significant (P>09 Students'
t test).
Bath conditions consisted ofheavy mineral
oil maintained at 36 5°C. Temperature was
monitored with a Digitec 581C digital
thermometer (United Systems Corp., Dayton,
OH) equipped with a 702 probe (Yellow
Springs Instrument Co., Yellow Springs, OH).
The system was accurate to +0 25°C.
Electrophysiological recording: In situ meas-
urements.-These techniques have been re-
ported by Conroy et al. (1979). Sensory NCV
for the "total hind limb" was based on the
delay (msec) for the sciatic nerve evoked
response, detected close to the iliac orbit after
a stimulus applied across the distal phalangeal
segments of the 1st and 4th hind-limb digits
(Stimulus Point No. 1). For proximal NCV
measurements, the stimulus was applied
across the sural nerve just above the ankle
(Stimulus Point No. 2). Conduction velocity
of the "distal" nerve segment was deter-
mined by obtaining the difference in delay
524MISONIDAZOLE NEUROTOXICITY IN THE MOUSE
(msec) between Stimulus Points Nos 1 and 2
and the measured distance between these
points.
Tumour implantation. - EMT6/Ro cells
were routinely maintained in a humidified
incubator at 37°C (3% C02, 97% air) by
twice-weekly transfer in Basal Modified
Eagle's Medium supplemented with 13%
(v/v) foetal calf serum. Cells were harvested
from such exponential cultures after a 10min
exposure to 0.05% trypsin and resuspended
in serum-free Hanks' Balanced Salt Solution
to a concentration of 107/ml. An aliquot
(0-02 ml) of this cell suspension (2 x 105 cells)
was injected i.m. into the gastrocnemius
muscle of the right leg of each mouse.
RESULTS
The Table presents results from 10
groups of animals given MISO by i.p.
injection over 1-12 weeks. In an effort to
test for latent drug effects or recovery,
Groups 3 and 5 were tested 1 week after
the last administered dose. No significant
difference in the electrophysiological para-
meters tested was found between the
experimental animals and the comparable
control groups (either PBS-treated or age-
matched, untreated mice). Although
Group 5 showed some reduction in sural
TABLE.-Effect of multiple i.p. administra-
tion of MISO on electrophysiological
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* Measurements 1 week after treatmen-t.
t 5 x /wk for 3 weeks.
t 5 x /wk for 4 weeks.
§ 1 0 ml/day saline, 5 x /wk for 3 weeks.
T No treatment.
11 5x/wk for 12 weeks.
NCV, the reduction was not statistically
significant (P> 0.9) from saline-injected
animals, nor was the reduction main-
tained with continued drug administration
(Group 6 or 7). A small increase in NCV
associated with age was also seen (Group
10). This increase was more noticeable in
tibial nerves than in sural nerves and
demonstrated that the drug treatment
would not prevent this increase.
The in situ measurements of peripheral
NCV obtained after 3 and 4 weeks of
chronic MISO administration (0.3 mg/g/
day, i.p., 5 x weekly) for groups of 4 or 6
mice, respectively, showed no significant
change (P> 0-9) in NCV compared to
concurrent PBS-treated control mice
(36.8 + 1-9 m/sec for 3 mice) or if the
proximal (33-3 + 4.5 m/sec) or distal
(36-8 + 1-9 m/sec) nerve segments were
analysed independently. All values were
corrected for temperature difference rela-
tive to 36-5°C. The velocities determined
by this method are also in reasonable
agreement with those obtained for the
isolated nerves, particularly since the in
situ measurements were a combination of
orthodromic and antidromic responses of
sensory and motor components, whereas
the isolated preparations were pre-
dominantly motor or sensory by virtue of
the isolation technique.
Since i.p. drug administration under
either acute or chronic conditions failed
to produce any significant demonstrable
change in peripheral NCV, relatively
large doses of drug (3 mg/g) were ad-
ministered to groups of 8 mice over a
period of 15 h by continuous i.v. infusion.
This significantly reduced the NCV of
sural (16-6%, P<0-1) and tibial (23-2%,
P< 0-05) nerves compared to untreated
control mice. However, PBS (pH 7-4)
infusion for 15 h in control mice produced
an equivalent reduction. When either the
drug-treated or saline-treated animals
were allowed 6 h after the end of the
infusion period to clear their water
burden, peripheral NCV for both groups
returned to normal. The observed reduc
tion is therefore attributed to the water
525P. J. CONROY ET AL.
load of the animals and not the presence
ofthe drug.
Finally, we investigated the effects of
acute i.p. administration of MISO (total
administered dose, 5 mg/g given 0 5 mg/g/
day or IP0 mg/g on alternate days) in
groups of 5 or 8 mice each of which at the
start of the treatment had a 450mg
tumour. The tumour was implanted close
to hind-limb nerves, to determine whether
toxic drug metabolites produced in the
tumour might diffuse the relatively short
distance to the nerve and produce damage
that would decrease the peripheral NCV.
In comparison to 5 untreated controls,
the reduction in NCV measured by the
in vitro method in the sural nerve of the
tumour-implanted limb (- 20%) under
both MISO dose regimens was similar to
that in mice which had tumour implants
and received no drug (PBS-injected con-
trols). Predominantly sensory (sural) and
motor (tibial and medial) nerves isolated
from the opposite hind limb or from the
forelimbs showed no significant change.
The presence of the tumour is therefore
the significant variable and the changes in
NCV are probably due to the physical
compression of the nerve produced by the
growing tumour.
DISCUSSION
There is reasonable agreement between
ourselves and other authors for normal
conduction velocity in mice (Hirst et al.,
1978, 1979; Von Burg et al., 1979). There-
fore, the issue at hand is not the ability to
measure conduction velocity in mice, but
rather the discrepancy in reported results
for MISO treatment.
Human studies have reported that the
initial symptoms of MISO toxicity are
associated with a sensory neuropathy that
appears to be related to a critical dose
(12 g/m2 in 3 weeks or 15 g/m2 in 6
weeks). The MISO dose inducing peri-
pheral neuropathy in humans is similar to
the exposure dose in the mouse that re-
sulted in a behavioural deficit and morpho-
logical damage to peripheral nerves (55-75
mmh; Coniroy et al., 1979). Hirst et al.
(1978) reported a decrease in motor NCV
in the mouse after a single i.p. injection of
1 mg/g. Our pharmacokinetic data for this
dose show that maximum serum con-
centration would be reached within 30
min, decay with a t1/2 of 1'5 h and produce
a drug exposure of 19'9 mmh. This is in
general agreement with the results of both
Hirst et al. (1978) and Flockhart et al.
(1978). Therefore, such a dose level is, at
best, less than one-half the critical ex-
posure level, and we have previously sug-
gested that the observed reduction in
NCV of these authors might be due to the
difficulty in controlling the temperature
of the nerve (Von Burg et al., 1979).
Hirst et al. (1979) repeated their obser-
vations by administering MISO at a
dosage of 0 15 mg/g in 36 doses over a
period of 18 days, and again found reduc-
tions in NCV. We have been unable to
confirm this result. We have treated
animals for up to 12 weeks (0.3 mg/g,
5 x weekly) and still could not detect any
changes in NCV. These latter animals are
the same ones that demonstrated morpho-
logical lesions and behavioural changes
within 3-4 weeks of drug administration
(Conroy et al., 1979).
Ifa single dose ofMISO were capable of
reducing motor NCV at an exposure of
19-9 mmh it can be assumed that a con-
tinuous infusion of drug at a mean serum
level of 2-5 mm for 15 h, to give an ex-
posure of 37-5 mmh, would produce an
effect greater than that observed by Hirst
et al. (1978, 1979) and significantly
different from a control group. This was
not found in the present study. Any asso-
ciated changes in NCV could be directly
related to a condition of hydration, per-
haps accompanied by oedema of the
nerves. Lastly, we tested the possibility
that cells within a tumour known to have
a hypoxic fraction of 20-25% at 400mg
wet wt (D. Siemann, personal communica-
tion, 1979) may produce a metabolite
responsible for the neurotoxicity, since it
is known that the drug undergoes a reduc-
tion to a more toxic species under hypoxic
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conditions (Varghese et al., 1976; Taylor &
Rauth, 1978). We could not find any
significant difference between the response
of nerves to MISO administration and the
appropriate control groups.
Although we can attribute the initial
findings of Hirst et al. (1978) to a problem
with temperature control as a variable in
the determination of NCV in mice, we are
at a loss to explain their most recent
results and have not been able to confirm
them. Earlier workers have demonstrated
that a nerve fibre actually undergoing
degeneration shows very little change in
conduction velocity (Gutmann & Holubar,
1950; Kaeser & Lambert, 1962; Thomas,
1971). Gross reductions in velocity of the
order reported by Hirst are generally asso-
ciated with segmental demyelination
(Dyck & Lambert, 1966; Gilliatt, 1966) or
axonal degeneration leading to demyelina-
tion (Post & McLeod, 1977). A current
clinical report by Kogelnik et al. (1979)
demonstrates no significant reduction in
peripheral NCV following MISO treat-
ment. However, some changes in distal
latency were noted. Therefore, in our
opinion, a single injection of MISO would
be unlikely to produce a change in NCV
Although chronic exposure to the drug
would allow the necessary time for axonal
degeneration and/or demyelination, our
results show that such changes do not
occur to a sufficient extent at the dose
level used, significantly to reduce nerve
conduction velocity.
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